NASDAQ:GERN Geron Q1 2025 Earnings Report $1.27 +0.03 (+2.42%) Closing price 04:00 PM EasternExtended Trading$1.27 0.00 (0.00%) As of 06:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Earnings HistoryForecast Geron EPS ResultsActual EPSN/AConsensus EPS -$0.03Beat/MissN/AOne Year Ago EPSN/AGeron Revenue ResultsActual RevenueN/AExpected Revenue$49.88 millionBeat/MissN/AYoY Revenue GrowthN/AGeron Announcement DetailsQuarterQ1 2025Date5/7/2025TimeBefore Market OpensConference Call DateWednesday, May 7, 2025Conference Call Time8:00AM ETConference Call ResourcesEarnings HistoryCompany Profile Geron Earnings HeadlinesGeron-Aktie erreicht 52-Wochen-Tief bei 1,19 US-DollarApril 17 at 2:48 PM | de.investing.comThe Gross Law Firm Notifies Shareholders of Geron Corporation(GERN) of a Class Action Lawsuit and an Upcoming DeadlineApril 17 at 5:45 AM | prnewswire.comTrump to unlock 15-figure fortune for America (May 3rd) ?We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men in America. Rickards has spent his fifty-year career in the innermost circles of the U.S. government and banking. And he believes Trump could soon release this frozen asset to the public. April 17, 2025 | Paradigm Press (Ad)GERN Investors Have the Opportunity to Lead the Geron Securities Fraud Lawsuit with Faruqi ...April 16 at 2:56 PM | gurufocus.comGERN Investors Have the Opportunity to Lead the Geron Securities Fraud Lawsuit with Faruqi & Faruqi, LLPApril 16 at 10:28 AM | globenewswire.comGeron stock hits 52-week low at $1.19 amid sharp annual declineApril 16 at 10:11 AM | investing.comSee More Geron Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Geron? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Geron and other key companies, straight to your email. Email Address About GeronGeron (NASDAQ:GERN), a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.View Geron ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles 3 Reasons to Like the Look of Amazon Ahead of EarningsTesla Stock Eyes Breakout With Earnings on DeckJohnson & Johnson Earnings Were More Good Than Bad—Time to Buy? Why Analysts Boosted United Airlines Stock Ahead of EarningsLamb Weston Stock Rises, Earnings Provide Calm Amidst ChaosIntuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth Ahead Upcoming Earnings HDFC Bank (4/18/2025)Intuitive Surgical (4/22/2025)Tesla (4/22/2025)Chubb (4/22/2025)Canadian National Railway (4/22/2025)Capital One Financial (4/22/2025)Danaher (4/22/2025)Elevance Health (4/22/2025)General Electric (4/22/2025)Lockheed Martin (4/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
